FierceBiotech

AstraZeneca drops lead T-cell receptor therapy from $200M Neogene buy

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...
VentureBeat

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...
FierceBiotech

Next-gen T-cell cancer player Neogene raises $110M with help from some big-name players

A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A. The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito ...
MM&M

AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics

AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...
Los Angeles Business Journal

AstraZeneca to Acquire Neogene Therapeutics

T-cell therapy company Neogene Therapeutics is being purchased by multinational pharma giant AstraZeneca in a deal potentially worth as much as $320 million that could greatly strengthen the regional ...